Rocket Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RCKT and other ETFs, options, and stocks.

About RCKT

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms.

CEO

Gaurav D. Shah

CEOGaurav D. Shah

Employees

299

Employees299

Headquarters

Cranbury, New Jersey

HeadquartersCranbury, New Jersey

Founded

1999

Founded1999

Employees

299

Employees299

RCKT Key Statistics

Market cap

366.33M

Market cap366.33M

Price-Earnings ratio

-1.41

Price-Earnings ratio-1.41

Dividend yield

—

Dividend yield—

Average volume

9.12M

Average volume9.12M

High today

$3.60

High today$3.60

Low today

$3.34

Low today$3.34

Open price

$3.48

Open price$3.48

Volume

2.68M

Volume2.68M

52 Week high

$22.01

52 Week high$22.01

52 Week low

$2.19

52 Week low$2.19

RCKT News

Seeking Alpha 6h

Rocket Pharmaceuticals announces CFO resignation

Healthcare Rocket Pharmaceuticals announces CFO resignation Aug. 26, 2025 10:03 AM ET Rocket Pharmaceuticals, Inc. (RCKT) Stock By: Nilanjana Basu, SA News Edit...

TipRanks 24h

Rocket Pharmaceuticals CFO Aaron Ondrey resigns to pursue other opportunities

In a regulatory filing, the company states: “On August 20, 2025, Aaron Ondrey resigned as Chief Financial Officer of Rocket Pharmaceuticals (RCKT), effective Se...

TipRanks 6d

Rocket Pharmaceuticals’ RP-A501 Study Advances with FDA Approval and Enhanced Safety Measures, Justifying Buy Rating

Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals and keeping the price target at $9.00. Elevate Your Investin...

Analyst ratings

53%

of 17 ratings

Buy

52.9%

Hold

41.2%

Sell

5.9%

More RCKT News

TipRanks 6d

Cautious Optimism: Hold Rating on Rocket Pharmaceuticals Amid Resumed Phase II Study with Protocol Changes

Needham analyst Gil Blum has maintained their neutral stance on RCKT stock, giving a Hold rating on August 11. Elevate Your Investing Strategy: Take advantage o...

TipRanks 6d

FDA Lifts Hold on Rocket’s Danon Disease Trial

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

People also own

Based on the portfolios of people who own RCKT. This list is generated using Robinhood data, and it’s not a recommendation.